Otonomy (OTIC) Appoints Jill Broadfoot to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Otonomy Appoints Jill Broadfoot to Board of Directors
August 19, 2021 7:30 AM EDTSAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors.
Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector, said David A. Weber, Ph.D., president and CEO of Otonomy. We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones.
Since 2018, Ms. Broadfoot has served as chief financial officer... More
